629662-23-3 Usage
General Description
(E)-Ethyl 3-(3,4-difluorobenzoyl)-1,1-dimethyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate is a complex chemical compound. It is an ester, which means it is derived from a combination of an alcohol (ethyl), an acid (3-(3,4-difluorobenzoyl)-1,1-dimethyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylic acid), and a carboxylic acid derivative (carboxylate). (E)-ethyl 3-(3,4-difluorobenzoyl)-1,1-dimethyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate has potential applications in the pharmaceutical industry, as it could possess biological activity due to its structure. However, its exact properties and potential uses need to be further investigated through research and testing.
Check Digit Verification of cas no
The CAS Registry Mumber 629662-23-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,2,9,6,6 and 2 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 629662-23:
(8*6)+(7*2)+(6*9)+(5*6)+(4*6)+(3*2)+(2*2)+(1*3)=183
183 % 10 = 3
So 629662-23-3 is a valid CAS Registry Number.
InChI:InChI=1/C24H22F2N2O3/c1-4-31-23(30)16-12-28(22(29)14-9-10-17(25)18(26)11-14)13-24(2,3)20-15-7-5-6-8-19(15)27-21(16)20/h5-12,27H,4,13H2,1-3H3
629662-23-3Relevant articles and documents
Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR)
Flatt, Brenton,Martin, Richard,Wang, Tie-Lin,Mahaney, Paige,Murphy, Brett,Gu, Xiao-Hui,Foster, Paul,Li, Jiali,Pircher, Parinaz,Petrowski, Mary,Schulman, Ira,Westin, Stefan,Wrobel, Jay,Yan, Grace,Bischoff, Eric,Daige, Chris,Mohan, Raju
supporting information; experimental part, p. 904 - 907 (2009/12/24)
Azepino[4,5-b]indoles have been identified as potent agonists of the farnesoid X receptor (FXR). In vitro and in vivo optimization has led to the discovery of 6m (XL335, WAY-362450) as a potent, selective, and orally bioavailable FXR agonist (EC50 = 4 nM, Eff = 149%). Oral administration of 6m to LDLR-/- mice results in lowering of cholesterol and triglycerides. Chronic administration in an atherosclerosis model results in significant reduction in aortic arch lesions.
